



In-Cell-Art Announces Extension of a second Research Service Agreement with a Global Independent Vaccine Company

Nantes – France, 26th of June, 2017 – In-Cell-Art (ICA), a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat acquired or inherited diseases, announces today that ICA and a global vaccine company signed a second research service agreement for the evaluation of Nanotaxi® formulated DNA vaccine to elicit immune response against undisclosed targets in the respiratory infectious disease field.

Under the terms of agreement, ICA will perform the entire project including in vivo animal studies for immunogenicity with the agreed financial support from the industrial partner which also gives technical assistance to enable ICA to make the proof of concept for the preclinical and clinical development of the bivalent vaccine. For low-dose and potent vaccine design, the delivery method uses ICA's Nanotaxi®, which can deliver genetic material directly into the cytosol to increase dramatically gene expression and stimulate the innate immune system.

Bruno Pitard, co-founder of In-Cell-Art, says *“In-Cell-Art is thrilled about this opportunity to extend the collaboration with this fully integrated vaccine company. We believe that Nanotaxi® has the potential to change the nucleic-acid based vaccination landscape through easier, more scalable, less expensive and logistically simpler, more effective vaccines that better prevent virus infectious diseases in the respiratory field. In addition to this collaboration, Nanotaxi® formulated nucleic-acid based vaccines has reached a crucial development step as the regulatory Good Laboratory Practice (GLP) toxicology studies has now been completed for the Nanotaxi®-based hepatocellular carcinoma vaccine candidate.”*

About In-Cell-Art

In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi ® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

1. ICANTibodies™

In the absence of recombinant antigen, ICANTibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANTibodies™

has allowed, in less than 3 years, the production of more than 300 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi, GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

2. ICA Nanotaxi®

- DNA Vaccine

ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies.

- mRNA Vaccine

Some other ICA Nanotaxi® are also being assessed in \$33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

- mRNA Replacement Therapy

Some other ICA Nanotaxi® are also developed to improve the limited efficacy and stability of mRNA therapeutics, leading to the dramatic increase in therapeutic protein expression without DNA-encoded gene.

3. ICAFectin® transfection reagents

ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy, Cell reports, EMBO J and more.

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

For further information please contact;

In-Cell-Art

Tel: 33 (0)6 73 19 12 02

E-mail: info@incellart.com

Website : <http://www.incellart.com>